Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-09-30

FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Keppra (levetiracetam) filed by UCB, Inc., resulting in labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Keppra (levetiracetam)

Snippet

SUPPL AP for KEPPRA (LEVETIRACETAM)